STOCK TITAN

CollPlant Biotechnologies Ltd Ordinary Shares - CLGN STOCK NEWS

Welcome to our dedicated page for CollPlant Biotechnologies Ordinary Shares news (Ticker: CLGN), a resource for investors and traders seeking the latest updates and insights on CollPlant Biotechnologies Ordinary Shares stock.

CollPlant Biotechnologies Ltd (NASDAQ: CLGN) is a pioneering company in regenerative and aesthetic medicine, specializing in the 3D bioprinting of tissues and organs and medical aesthetics. The company's core technology is its recombinant human collagen (rhCollagen), produced through proprietary plant-based genetic engineering. CollPlant's innovative products address diverse fields of tissue repair, aesthetics, and organ manufacturing, marking a new era in regenerative medicine.

CollPlant's flagship rhCollagen bioink product line is optimized for 3D bioprinting applications, including drug discovery, tissue testing, and the development of transplantable tissues and organs. The company's unique Vergenix™ line includes a soft tissue repair matrix for tendinopathy treatment and a wound repair matrix that promotes rapid healing of acute and chronic wounds.

In the medical aesthetics market, CollPlant is advancing its regenerative breast implants and dermal fillers. The company has formed strategic partnerships, including a notable collaboration with AbbVie for the development of dermal and soft tissue fillers, triggering milestone payments and potential future royalties.

Recent achievements include the initiation of pre-clinical trials for regenerative breast implants and progress in large-animal studies demonstrating tissue regeneration and safety. In addition, CollPlant's advanced bioinks are facilitating the bio-fabrication of human tissues and organs in collaboration with industry leaders.

Financially, CollPlant reported significant revenue increases due to milestone payments and product sales, although it continues to invest in research and development to maintain its leading position in the market. The company's cash and cash equivalents provide a robust runway for at least two years of operation, supporting ongoing and future projects.

CollPlant's commitment to sustainability is reflected in its plant-based production process and adherence to Environmental, Social, and Governance (ESG) principles. The company joined the United Nations Global Compact to further its sustainable corporate governance goals.

Rhea-AI Summary
CollPlant Biotechnologies (CLGN) announces financial results for 2023, highlighting progress in dermal filler and regenerative breast implant programs. The company ended 2023 with $26.7 million in cash. Collaboration with AbbVie and Stratasys advanced, triggering milestone payments. Regenerative breast implants showed promise in large-animal studies, targeting a $2.9 billion market. Intellectual property gains and ESG efforts were also notable.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
-
Rhea-AI Summary
CollPlant Biotechnologies (CLGN) schedules conference call to discuss financial results for the full year of 2023 on April 4, 2024, at 10:00 a.m. U.S. EDT.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
-
News
Rhea-AI Summary
CollPlant Biotechnologies (CLGN) CEO Yehiel Tal highlights key achievements in 2023, including progress with AbbVie collaboration and Stratasys partnership. The company focuses on regenerative and aesthetic medicine, with a pipeline of innovative products like regenerative breast implants and gut-on-a-chip tissue model.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
none
Rhea-AI Summary
CollPlant Biotechnologies (CLGN) CEO to present at Octane Aesthetic Tech Forum on 3D Bioprinted Regenerative Breast Implants
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
CollPlant Biotechnologies (CLGN) Initiates Pre-Clinical Trial for Regenerative Breast Implants, Aiming to Revolutionize the $2.6 Billion Market
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.32%
Tags
-
Rhea-AI Summary
CollPlant Biotechnologies (Nasdaq: CLGN) announced a $10 million milestone payment from partner AbbVie Inc., a $29 million cash runway, and financial results for the third quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.63%
Tags
Rhea-AI Summary
CollPlant Biotechnologies (CLGN) to report Q3 2023 financial results on November 29, 2023, followed by a conference call and webcast. Investors can participate in the call using the provided dial-in information or the Call me™ feature. A live webcast will also be available, and questions for management can be submitted in advance via email.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
-
Rhea-AI Summary
CollPlant Biotechnologies has secured a patent from the U.S. Patent and Trademark Office for its photocurable dermal filler product candidate. The patent covers a method of filling tissue space under the epidermis by introducing a polymerizable filler solution and applying external light for in-situ polymerization. This patent strengthens CollPlant's intellectual property in the U.S. market and expands the potential uses for its rhCollagen technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.11%
Tags
none
-
Rhea-AI Summary
CollPlant Biotechnologies joins UN Global Compact to strengthen commitment to sustainability in regenerative and aesthetics medicine industry
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.66%
Tags
none
Rhea-AI Summary
CollPlant Biotechnologies to participate in H.C Wainwright Annual Growth Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.66%
Tags
conferences

FAQ

What is the current stock price of CollPlant Biotechnologies Ordinary Shares (CLGN)?

The current stock price of CollPlant Biotechnologies Ordinary Shares (CLGN) is $3.41 as of December 20, 2024.

What is the market cap of CollPlant Biotechnologies Ordinary Shares (CLGN)?

The market cap of CollPlant Biotechnologies Ordinary Shares (CLGN) is approximately 42.4M.

What does CollPlant Biotechnologies Ltd do?

CollPlant specializes in regenerative and aesthetic medicine, focusing on 3D bioprinting of tissues and organs, and medical aesthetics.

What is rhCollagen?

rhCollagen is CollPlant's proprietary recombinant human collagen produced using plant-based genetic engineering technology.

What are CollPlant's main products?

CollPlant's products include rhCollagen bioinks for 3D bioprinting, Vergenix soft tissue repair and wound repair matrices, and regenerative breast implants.

What are the recent achievements of CollPlant?

CollPlant initiated pre-clinical trials for regenerative breast implants, progressed in large-animal studies, and received milestone payments from AbbVie.

Who are CollPlant's strategic partners?

Key partners include AbbVie for dermal and soft tissue fillers and Stratasys for bio-fabrication of tissues and organs.

Where does CollPlant operate?

CollPlant operates primarily in the United States, Canada, Europe, and Israel.

What are CollPlant's financial highlights?

CollPlant reported significant revenue increases, mainly from milestone payments and product sales, and maintains a strong cash position.

How is CollPlant contributing to sustainability?

CollPlant uses plant-based genetic engineering for its products, reduces environmental impact, and follows ESG principles, including joining the UN Global Compact.

What is the market potential for CollPlant's products?

CollPlant's products target large markets in tissue repair, medical aesthetics, and organ manufacturing, with ongoing development and commercialization efforts.

How can investors participate in CollPlant's conference calls?

Investors can join conference calls using the provided dial-in numbers or access live webcasts through the company's investor relations website.

CollPlant Biotechnologies Ltd Ordinary Shares

Nasdaq:CLGN

CLGN Rankings

CLGN Stock Data

42.38M
7.82M
10.16%
12.23%
0.11%
Biotechnology
Healthcare
Link
United States of America
Rehovot